The Molecular Biology Core (Core D) consists of two components. 1) The first component (directed by Scott McIvor, Ph.D.) is a proposal to support efforts in retroviral marking of primitive progenitor populations and to use sensitive molecular genetic methods to detect the marked progeny of these progenitors in subsequent hematopoietic cultures, xenotransplants, human autologous and cord blood allogeneic transplants described in projects 1,2,3,4 and 5. The core leader will provide a quality controlled source of retroviral vector for use in transduction experiments and will analyze culture and transplant cell samples to detect presence of the retroviral marker and to identify specific integration events which establish relationships between marked primitive progenitors and their myeloid and lymphoid progeny 2) The second component of Core D (directed by Wesley Miller, M.D) is a proposal to use sensitive molecular genetic methods to assess the presence and extent of contamination with cells containing the BCR/ABL gene rearrangement characteristic of CML in progenitor culture, selected and expanded stem cell inocula and post- transplant patient samples resulting from clinical trials proposed in Project 3 and for CML patients transplanted in project 5. In addition, the two core leaders will combine efforts to detect simultaneously the presence of a retroviral marker and BCR/ABL gene rearrangement in hematopoietic colonies derived from relapsing CML patients following autologous transplantation. These studies will be used to determine the contribution of the selected and expanded primitive progenitor population to recurrence of CML following autologous transplantation. The molecular biology studies described in Core D provide invaluable support to the projects exploring the ontogeny, maintenance and multilineage differentiation of primitive hematopoietic progenitors in vitro and in vivo as well as those exploring the origin of cells responsible for relapse after autologous stem cell transplantation in CML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-05
Application #
6103012
Study Section
Project Start
1999-07-06
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Pennell, Christopher A; Barnum, Jessie L; McDonald-Hyman, Cameron S et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther 26:1423-1434
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933

Showing the most recent 10 out of 395 publications